--- title: "Roadmap Preview: Biomarker-Guided And Pharmacogenomic-Informed Dosing" description: InsightRX to extend Nova platform beyond therapeutic drug monitoring (TDM) into biomarker-guided dosing (BMX) and pharmacogenomic-informed dosing (PGx). image: https://blog.insight-rx.com/hubfs/Blog%20Generic%20Product%20Innovation.png --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://blog.insight-rx.com/) - For Providers - Solutions - [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd) - [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future) - Products - [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova) - [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo) - [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules) - [For Life Sciences](https://www.insight-rx.com/life-sciences) - Overview - [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences) - Products - [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova) - [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra) - Platform - [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning) - [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support) - Resources - Science - [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science) - [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications) - [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova) - Explore - [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories) - [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers) - [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software) - [Blog](https://blog.insight-rx.com/resources) - [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources) - [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership) - Company - About - [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about) - [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership) - [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board) - [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers) - [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers) - Press - [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases) - [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) Product Innovation # Roadmap Preview: Biomarker-Guided And Pharmacogenomic-Informed Dosing - Published April 5, 2022 By [Jon Faldasz](https://blog.insight-rx.com/resources/author/jon-faldasz) ![](https://blog.insight-rx.com/hubfs/Blog%20Generic%20Product%20Innovation.png) On our Year in Review webinar, presenters Stephanie Hughes, PharmD, BCIDP, Clinical Applications Specialist, and Jon Faldasz, PharmD, BCPS, our Senior Director of Product & Customer Experience, shared a sneak peek at an exciting expansion on the horizon. In 2022, InsightRX will extend the InsightRX Nova platform beyond therapeutic drug monitoring (TDM) into two other categories: biomarker-guided dosing and pharmacogenomic-informed dosing. --- Using Biomarker-Guided Dosing to Prevent Chemotherapy-Induced Neutropenia To understand biomarker-guided dosing, it’s helpful to look at how TDM functions. In TDM, we feed a patient’s drug measurement through a pharmacokinetic model and compare it to predicted measured levels for that patient in order to create patient-specific pharmacokinetic parameters, which we then use to assess drug exposure and choose a treatment regimen. However, drug exposure in and of itself is rarely what we ultimately care about: instead, drug exposure is often a surrogate measure for some unmeasurable exposure-dependent outcome. For example, with vancomycin, our goal is clinical cure via bacterial eradication, which in theory would be measured by the decrease in bacterial load. As we can’t feasibly measure that outcome, we instead use a pharmcokinetically measurable correlate of clinical cure and bacterial eradication: AUC.  In some situations, however, we can measure the desired exposure-dependent outcome, either directly or indirectly. In those cases, we can bypass the intermediary correlates entirely, instead using a value (or surrogate value) fed into a pharmacodynamic model to assess the impact of a potential dose, which we can similarly then adjust as needed to optimize outcomes. This is called biomarker-guided dosing, or BMx.  One example of this type of biomarker-guided dosing is the prevention of chemotherapy-induced neutropenia. In October 2021, [we partnered with Memorial Sloan Kettering Cancer Center](https://blog.insight-rx.com/press-releases/inaugural-cohort-cutting-edge-innovation-hub-transform-cancer-care) to develop a pharmacodynamic model that describes the direct relationship of drug exposure to quantitative changes in neutrophils. When patients start a chemotherapy regimen, we will track changes in their absolute neutrophil count (ANC) to plot a pharmacodynamic trajectory which will reveal a predicted nadir and a timeline for ANC decline. Clinicians can then adjust the chemotherapy regimen mid-stream in response to these predictions to ensure an optimal trajectory for ANC, without undue risk or loss of efficacy.  Paving the Way for Pharmacogenomic-Informed Dosing: Introducing InsightRX PGx   We are currently building a pharmacogenomic software solution, InsightRX PGx, that interfaces with our other solutions and finally brings clinically applicable and actionable value to pharmacogenetic and pharmacogenomic data. Accessing the software platform will be similar to InsightRX Nova, with options to launch InsightRX PGx either through a standalone web application or directly from within a patient chart in an EHR. When clinicians access InsightRX PGx, the software will request genetic and genomic information on the patient from central laboratories around the world.  Once this information is retrieved, InsightRX PGx will cross-reference the raw genetic data to established pharmacogenetic and pharmacogenomic databases and present the interpreted information to the clinician. Using the patient’s genomic data, the platform will then provide the clinician an individualized, quantitative patient-specific dosing guide, with application to the patient’s current treatment as well as any future drug therapy. If the drug in question is represented in InsightRX Nova, then the patient’s pharmacogenetic data is imported into InsightRX Nova and is used to aid in patient-specific pharmacokinetic and pharmacodynamic predictions, adding another level of individualization to the modeling and predictions.   As aggregated pharmacogenomic-informed dosing data is integrated into the InsightRX Apollo analytics solution, clients can view their own data and search for improvement opportunities. At the same time, the InsightRX Data Science team can analyze this data to look for new covariates and new ways to refine our pharmacokinetic models within InsightRX Nova. This cycle of continuous improvement generates more precise, accurate dosing with every iteration, bringing us closer to our goal of delivering optimized dosing for every patient.  [oncology](https://blog.insight-rx.com/resources/tag/oncology) [pharmacogenomics](https://blog.insight-rx.com/resources/tag/pharmacogenomics) #### On this page… About the author [Jon Faldasz, PharmD, BCPS](https://blog.insight-rx.com/resources/author/jon-faldasz) Senior Director of Product & Customer Experience Jon joined InsightRX in 2019 after a decade of practice as an Infectious Disease Pharmacist in adults and pediatrics. He is a bona fide PK nerd, and will chat your ear off gleefully if given the chance. **Connect with us to get the latest blog updates, instantly sent to your inbox** ## Dig deeper. Explore related articles and additional posts on the InsightRX blog. [Thought Leadership Nov 6, 2024 Heparin: the puppy who won’t sit still](https://blog.insight-rx.com/resources/heparin-dosing-pharmacokinetics-mipd) [Thought Leadership Aug 15, 2023 Simulation Demonstrates Potential Effectiveness of Model-Informed Precision Dosing for Heparin](https://blog.insight-rx.com/resources/simulation-demonstrates-potential-effectiveness-model-informed-precision-dosing-heparin) [Thought Leadership Sep 7, 2022 The Evolution of Therapeutic Drug Monitoring for Tacrolimus](https://blog.insight-rx.com/resources/evolution-therapeutic-drug-monitoring-tacrolimus) #### What We Do ##### For Providers - [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova) - [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo) - [Drug Modules](https://www.insight-rx.com/provider/drug-modules) ##### For Life Sciences - [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova) - [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra) - [Companion Applications](https://www.insight-rx.com/life-sciences/nova#companion-applications) #### How We Do It ##### Platform - [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning) - [Integrations](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support](https://www.insight-rx.com/platform/success-support) ##### Science - [Data Science](https://www.insight-rx.com/data-science) - [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications) #### Information ##### Resources - [Success Stories](https://www.insight-rx.com/success-stories) - [White Papers](https://www.insight-rx.com/white-papers) - [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software) - [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova) ##### Blog - [All Posts](https://blog.insight-rx.com/resources) - [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership) #### About - [Our Story](https://www.insight-rx.com/about) - [Leadership](https://www.insight-rx.com/leadership) - [Advisory Board](https://www.insight-rx.com/advisory-board) - [Our Customers](https://www.insight-rx.com/customers) - [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media](https://blog.insight-rx.com/press-releases?section=media) - [Careers](https://www.insight-rx.com/careers) - [Contact](https://www.insight-rx.com/contact-us) --- ![CE marking](https://blog.insight-rx.com/hubfs/ce-mark-white.svg) InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1. InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance. 740-05000-REC-01 · 08/2025 --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://www.insight-rx.com/) 548 Market Street #88083 San Francisco, CA 94104 --- © 2026 InsightRX, Inc. All rights reserved. [Privacy Policy](https://www.insight-rx.com/privacy-policy) Cookie Preferences ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Jon Faldasz, PharmD, BCPS - Senior Director of Product & Customer Experience", "url" : "https://blog.insight-rx.com/resources/author/jon-faldasz" }, "dateModified" : "2025-12-15T00:06:08.232Z", "datePublished" : "2022-04-05T23:59:00.000Z", "headline" : "Roadmap Preview: Biomarker-Guided And Pharmacogenomic-Informed Dosing", "image" : [ "https://blog.insight-rx.com/hubfs/Blog%20Generic%20Product%20Innovation.png" ], "mainEntityOfPage" : { "@id" : "https://blog.insight-rx.com/resources/roadmap-preview-biomarker-guided-pharmacogenomic-informed-dosing", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.insight-rx.com/hubfs/insightrx_logo_color%20500%20x%20250-1.png" }, "name" : "InsightRX" } } ```